PMC:7546122 / 3423-3705 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T18","span":{"begin":54,"end":62},"obj":"Disease"},{"id":"T19","span":{"begin":237,"end":261},"obj":"Disease"},{"id":"T20","span":{"begin":263,"end":271},"obj":"Disease"}],"attributes":[{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A19","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A20","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"The question is of significant clinical relevance, as SARS-CoV-2 cross-neutralizing antibodies in IVIGs, if they were present, might afford some protection to people with immune deficiencies and may even represent a treatment option for coronavirus disease 2019 (COVID-19) patients."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T30","span":{"begin":214,"end":215},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"The question is of significant clinical relevance, as SARS-CoV-2 cross-neutralizing antibodies in IVIGs, if they were present, might afford some protection to people with immune deficiencies and may even represent a treatment option for coronavirus disease 2019 (COVID-19) patients."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T5","span":{"begin":171,"end":190},"obj":"Phenotype"}],"attributes":[{"id":"A5","pred":"hp_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/HP_0002721"}],"text":"The question is of significant clinical relevance, as SARS-CoV-2 cross-neutralizing antibodies in IVIGs, if they were present, might afford some protection to people with immune deficiencies and may even represent a treatment option for coronavirus disease 2019 (COVID-19) patients."}

{"project":"LitCovid-sentences","denotations":[{"id":"T20","span":{"begin":0,"end":282},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The question is of significant clinical relevance, as SARS-CoV-2 cross-neutralizing antibodies in IVIGs, if they were present, might afford some protection to people with immune deficiencies and may even represent a treatment option for coronavirus disease 2019 (COVID-19) patients."}

{"project":"LitCovid-PubTator","denotations":[{"id":"83","span":{"begin":54,"end":64},"obj":"Species"},{"id":"84","span":{"begin":159,"end":165},"obj":"Species"},{"id":"85","span":{"begin":273,"end":281},"obj":"Species"},{"id":"86","span":{"begin":237,"end":261},"obj":"Disease"},{"id":"87","span":{"begin":263,"end":271},"obj":"Disease"}],"attributes":[{"id":"A83","pred":"tao:has_database_id","subj":"83","obj":"Tax:2697049"},{"id":"A84","pred":"tao:has_database_id","subj":"84","obj":"Tax:9606"},{"id":"A85","pred":"tao:has_database_id","subj":"85","obj":"Tax:9606"},{"id":"A86","pred":"tao:has_database_id","subj":"86","obj":"MESH:C000657245"},{"id":"A87","pred":"tao:has_database_id","subj":"87","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The question is of significant clinical relevance, as SARS-CoV-2 cross-neutralizing antibodies in IVIGs, if they were present, might afford some protection to people with immune deficiencies and may even represent a treatment option for coronavirus disease 2019 (COVID-19) patients."}